Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Jianrong Wu"'
Autor:
Richard Gorlick, Jianrong Wu, Stephen T. Keir, Christopher L. Morton, E. Anders Kolb, C. Patrick Reynolds, John M. Maris, Malcolm A. Smith, Peter J. Houghton, Min H. Kang
Publikováno v:
Pediatric bloodcancer. 55(2)
Background Seneca Valley virus (NTX-010) is a non-recombinant, replication competent RNA virus that is undergoing phase 1 clinical trials in adults for tumors with neuroendocrine characteristics. Here we have evaluated the antitumor activity of NTX-0
Autor:
Richard B. Lock, Stephen T. Keir, Jianrong Wu, Malcolm A. Smith, E. Anders Kolb, Hernan Carol, Richard Gorlick, John M. Maris, Christopher L. Morton, Peter J. Houghton, Min H. Kang, C. Patrick Reynolds
Publikováno v:
Pediatric bloodcancer. 55(1)
MLN8237 is a small molecule inhibitor of Aurora Kinase A (AURKA) that is currently in early phase clinical testing. AURKA plays a pivotal role in centrosome maturation and spindle formation during mitosis.MLN8237 was tested against the Pediatric Prec
Autor:
Stephen T. Keir, Jianrong Wu, Peter J. Houghton, John M. Maris, Mayamin Tajbakhsh, Malcolm A. Smith, Joshua Courtright, Richard B. Lock, Christopher L. Morton, E. Anders Kolb, C. Patrick Reynolds
Publikováno v:
Pediatric bloodcancer. 51(1)
Background Sunitinib is an orally bioavailable, multi-targeted tyrosine kinase inhibitor with selectivity for PDGF receptors, VEGF receptors, FLT3, and KIT. Procedures Sunitinib was tested at concentrations ranging from 0.1 nM to 1.0 µM against 23 c